Cereno Scientific (CRNO) ABGSC Investor Days summary

Strategic focus and disease areas

• Shifted focus to rare cardiovascular and pulmonary diseases, aiming for disease-modifying therapies addressing root causes.

• Targeting pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF), and thrombosis, all with high unmet medical needs.

• Emphasizing HDAC inhibition and epigenetic modulation as core scientific approaches.

Drug development programs and clinical progress

• Lead program CS1 (repurposed HDAC inhibitor) showed positive phase II-A results in PAH, with strong safety and efficacy signals, including improved REVEAL Risk Score and functional class in patients.

• Compassionate use/expanded access for CS1 approved by FDA, with long-term data readouts expected in H1 next year.

• Second program CS014 (novel, deuterated HDAC inhibitor) in phase I for IPF, with phase I completion and phase II planning targeted for H1 2026.

• Third program CS585 (IP receptor agonist) in preclinical stage, aiming for phase I in 2026, with preclinical data showing thrombosis prevention without bleeding risk.

Clinical and regulatory milestones

• CS1 phase II-B or pivotal trial discussions with FDA planned for H1 next year, with approval targeted by end of H1.

• Long-term compassionate use data and Fluidda imaging results expected in H1, supporting further regulatory steps.

• CS014 phase I completion and regulatory submission for phase II expected in H1 2026.

• CS585 preclinical work to be completed by H1 2026.